Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

By measuring portal pressure of hepatocirrhotic dogs of bile duct ligation directly, and detecting portal system flow in patients with hepatic cirrhosis by ultrasound doppler, we studied the portal hemodynamic effects of Radix Salviae Miltiorrhizae (RSM). After intravenous administration of RSM in hepatocirrhotic dogs, the portal venous pressure (PPV), wedge hepatic venous pressure (WHVP), and hepatic venous pressure gradient (HVPG) were significantly decreased (P < 0.05-0.01), but the mean arterial pressure (MAP), and heart rate (HR) unchanged (P > 0.05). After long-term administration of RSM (10-12 weeks), the diameter of portal vein (DPV) and splenic vein (DSV), the flow of portal vein (QPV), and splenic vein (QSV) in patients with hepatic cirrhosis were significantly decreased respectively (P < 0.05-0.001). Hypodynamia, abdominal distension, anorexia and liver function (ALT) were improved partially after administration of RSM in patients with hepatic cirrhosis. Side-effects of RSM were not found. The results demonstrated that RSM is an effective drug of depressing portal pressure with few side-effects.
Zhonghua Nei Ke Za Zhi 1997 Jul
PMID:[Effects of radix Salviae miltiorrhizae on hemodynamics of portal hypertension: clinical and experimental study]. 1043 44

Paraffin-embedded liver tissue from 60 biopsied or autopsied cases, including 20 cases each of acute mild hepatitis, chronic active hepatitis and active cirrhosis were studied with immunohistochemical double labelling technique by using polyclonal anti-Fas and anti-Fas ligand. The detection rates for Fas and Fas ligand were 76.7% (46/60) and 70.0% (42/60), respectively. Fas antigen was located in cytoplasm of hepatocytes. Fas ligand was expressed mainly in infiltrating lymphocytes in portal or periportal areas (34/42, 80.9%) and also in the cytoplasm of some hepatocytes (25/42, 59.5%). The distribution of Fas ligand-positive hepatocytes was similar to that of Fas-positive hepatocytes in liver tissue. The positive cells were scattered in the intralobular areas in acute mild hepatitis, but they were more commonly aggregated in periportal areas, especially near the edges of the piecemeal necrosis region or in infiltrating mononucleocytes in chronic active hepatitis and active cirrhosis, Double labelling studies showed that both Fas and Fas ligand might be expressed in the same or different hepatocytes of the same area. Our results suggest that Fas-Fas ligand system may play an important role in liver cell injury due to hepatitis B virus infection.
Zhonghua Nei Ke Za Zhi 1997 Oct
PMID:[Expression of Fas and Fas ligand in liver tissue infected with hepatitis B virus]. 1043 77

Serum transforming growth factor beta 1 (TGF beta 1) concentration was determined in 47 patients with primary hepatic carcinoma (PHC) and 77 patients with various liver diseases and gastrointestinal tumors by means of enzyme-linked immunosorbent assay system. The result revealed that serum TGF beta 1 level of PHC patients were significantly higher (257.6 +/- 126.0 micrograms/L) than those in normal subjects (81.5 +/- 43.5 micrograms/L), in patients with hepatitis (152.4 +/- 98.4 micrograms/L), cirrhosis (191.8 +/- 96.3 micrograms/L), hepatic benign tumor (91.9 +/- 37.9 micrograms/L), metastatic liver cancer (146.4 +/- 73.7 micrograms/L) and gastrointestinal tumor (128.7 +/- 56.4 micrograms/L) (P < 0.01 or 0.05). Serum TGF beta 1 level was elevated in 34 of 47 (72.3%) PHC patients, including 5 of 7 (91.4%) small (< 5 cm) PHC patients. The sensitivity and specificity of diagnosis of TGF beta 1 in PHC were 72.3% and 77.9%, respectively. The diagnostic positivity was 78.5% in AFP-negative PHC patients. The combined assay of serum TGF beta 1 and AFP could further raise the detection rate of PHC up to 93.6%. Above results suggest that serum TGF beta 1 might be a candidate for a novel tumor marker for diagnosis and monitoring of PHC.
Zhonghua Nei Ke Za Zhi 1997 Oct
PMID:[Clinical evaluation of serum transforming growth factor beta 1 assay in the diagnosis of primary hepatic carcinoma]. 1043 81

The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy (HE) in cirrhosis based on the published evidences and panelists' consensus. The guidelines provided recommendations for the diagnosis and management of hepatic encephalopathy including minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy (OHE) emphasizing the importance on screening MHE in patients with end-stage liver diseases. The guidelines emphasized that early identification and prompt treatment are essential to improve the prognosis of HE. The principles of treatment mainly consist of eliminating precipitating factors, treating hyperammonemia to improve acute neuropsychiatric abnormalities rapidly, primary and secondary prophylaxis.
Zhonghua Nei Ke Za Zhi 2018 Oct 01
PMID:[Guidelines on the management of hepatic encephalopathy in cirrhosis]. 3029 30


<< Previous 1 2 3 4 5